What Should Doctors Know About FDA’s Black Box Change for Hormone Replacement Therapy Drugs?

A Keck Medicine of USC breast surgeon discusses the FDA’s decision — and whether using HRT to treat menopause symptoms actually affects breast cancer risk.

By
January 28, 2026
8 min

Keck Medicine of USC

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

#1

Mayo Clinic

Rochester, MN
Key Differentiators
- Menopause
- Endocrinology
- Breast Cancer
- Women's Health
#2

Brigham and Women's Hospital

Boston, MA
Key Differentiators
- Endocrinology
- Breast Cancer
- Women's Health
#3

University of California, San Francisco (UCSF) Medical Center

San Francisco, CA
Key Differentiators
- Menopause
- Endocrinology
- Breast Surgery
- Women's Health
#4

Keck Medicine of USC

Los Angeles, CA
Key Differentiators
- Breast Surgery
- Women's Health
- Endocrinology
#5

Johns Hopkins Medicine

Baltimore, MD
Key Differentiators
- Endocrinology
- Women's Health
- Breast Cancer

What Should Doctors Know About FDA’s Black Box Change for Hormone Replacement Therapy Drugs?

Top Institutions in Cardiology

Mayo Clinic

Brigham and Women's Hospital

University of California, San Francisco (UCSF) Medical Center

Keck Medicine of USC

Johns Hopkins Medicine

Original Source(s)

What Should Doctors Know About FDA’s Black Box Change for Hormone Replacement Therapy Drugs?

Related Content

Effects of Setup Errors on Dose Distribution in Hypofractionated Radiotherapy for Left-Sided Radical Breast Cancer

Case Study: Evaluation of Anticancer Treatment and Cardiovascular Safety in a Breast Cancer Patient with Pre-existing Cardiovascular Conditions

Errors in Abstract and Table 1